Dry January doesn't have to mean sober January — at least for the 21 percent of participants turning to cannabis or CBD to make it through the month.
According to a survey by Civic Science, 67 percent of Dry January participants, or those choosing to abstain from alcohol consumption for the month of January, reported they are replacing alcohol with something — whether that be mocktails and alcohol-free beers or sodas and seltzers.
The largest share, 21 percent, said they would enjoy cannabis or non-psychoactive CBD in place of alcohol. The preference for substitutes wasn't uniform across all respondents. Cannabis was the most popular substitute among the youngest respondents with 34 percent of 21- to 24-year-olds preferring it. Among the 55 and older crowd, by contrast, just 9 percent reported they'd enjoy cannabis or CBD instead of alcohol, and 54 percent reported they'd stay the course without any support.
Dry January's Growing Popularity
Interest in Dry January has climbed over the recent years. At the close of 2022, about 41 percent of respondents in a separate survey by Civic Science reported they were "somewhat to very likely" to participate in Dry January come 2023. That's in-line with pre-pandemic data for the start of 2020, but slightly behind 2022 responses, which rebounded after a lag in interest during the 2021 pandemic year.
As with the preference for cannabis, interest in Dry January tends to vary by age — and younger generations are leading the charge. For the year of 2023, more than half of the youngest respondents, aged 21 to 24 years old, said they were "somewhat to very likely" to participate versus just 41 percent of those 55 and older.
Studies suggest social media is contributing to a growing reluctance to drink with younger generations fearful of consequences if their drunk escapades are documented on the internet. According to 2019 research from Google, 49 percent of Generation Z reports their image online is "always at the back of their mind when they go out socializing and drinking." Some 76 percent reported it is important to have control of "all aspects of their life at all times," according to the research.
A subvariant of the omicron COVID-19 variant called BA.2 is causing an outbreak overseas. Now, some health experts worry it could also lead to an increase in COVID-19 cases in the U.S. Dr. Amesh Adalja, infectious disease specialist and senior scholar at Johns Hopkins Center for Health Security, joins Cheddar News to discuss.
Dr. Alan Kaplin, Chief Scientific Officer of MyMD, joins Cheddar Innovates to discuss how the MYMD-1 is on track to be the first FDA-approved drug to treat aging and age-related diseases.
Tyler Hayes, CEO of Atom Limbs, joins Cheddar Innovates to discuss how the Atom Touch prosthetic is different from other prosthetics on the market, and how the Atom Limbs team of former Apple and Tesla leaders are bringing innovation into this industry.
Nouveau Monde Graphite says it wants to power the sustainable energy revolution. The Canadian company is developing carbon-neutral battery materials to serve the growing EV and cleantech markets and is doing so via a mining and manufacturing operation in Quebec. Eric Desaulniers, founder, president & CEO of Nouveau Monde Graphite, joins Cheddar News' Closing Bell to discuss.
Health experts are warning an even more contagious subvariant of Omicron, known as BA.2, could soon lead to another surge in Covid cases here in the U.S. The variant has already driven cases to skyrocket in China and Europe, which has historically served as a preview to the pattern the U.S. has seen throughout the pandemic. This comes at a time when protection from booster shots is waning for most people who got them. Dr. Jen Caudle, Family Physician & Associate Professor at Rowan University, explains what we can do to protect ourselves against the new variant and how we should act as warnings of another surge rise.
Catching you up on what you need to know Mar 24, 2022, with NATO meeting updates, Ukraine retaking suburbs around Kyiv, the spread of omicron subvariant BA.2 in China, Google Pay launching a third-party billing option, and a 16-year-old is suspected of being the Lapsus$ mastermind behind hacks of Microsoft and others.
Cannabis producer Cresco Labs is acquiring rival Columbia Care in a $2 billion all-stock deal, creating the largest U.S. cannabis company by sales. The deal, which is expected to close in the fourth quarter of 2022, is one of the biggest in the industry's history and would make Cresco the dominant player in a market projected to reach $46 billion in revenue by 2026. Charlie Bachtell, CEO of Cresco Labs, joins Cheddar News' Closing Bell to discuss.
Moderna announced it's seeking emergency use approval for its COVID-19 vaccine from the FDA for children under 6 years old. A former FDA associate commissioner and the president and co-founder of the Center for Medicine in the Public Interest (CMPI) Peter Pitts joined Cheddar News to talk about the timeline, benefits, and risks that come with the approval of the vaccine. "We want to protect their parents and their grandparents and their caregivers and their daycare providers, so it's all about protecting not just the kids but all around the people that are surrounding those kids," he said.
Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers. The company announced early findings Wednesday from a study of children younger than 6.
Catching you up on what you Need to Know on Mar 23, 2022, as NATO meets in Brussels to discuss Ukraine, mortgage rates rise, Justin Trudeau is set to lead Canada until 2025, tornadoes sweep through Louisiana, California may do away with SATs, and a Starbucks in Seattle unionizes.
